SciSparc

Company Overview

Snapshot

Founded in August 2004, SciSparc operates with 1-10 employees. The company has raised $63.76 million across 12 funding rounds and went public on NASDAQ in March 2017.

Business overview

SciSparc is a clinical-stage pharmaceutical company specializing in the development and enhancement of cannabinoid-based pharmaceuticals. The company focuses on drug development programs utilizing THC and non-psychoactive cannabidiol (CBD) for central nervous system disorders. Its product pipeline includes SCI-110 for Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for pain; and SCI-210 for autism spectrum disorder and epilepsy. SciSparc operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals market.

Strategic signal

In October 2025, SciSparc completed the acquisition of a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio. This strategic move signals SciSparc's intent to consolidate its clinical assets and potentially expand its market reach and development capabilities within the pharmaceutical industry.

Company Intelligence Q&A

What was a significant corporate development for SciSparc in October 2025?

In October 2025, SciSparc announced the closing of the acquisition of a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio.

What was the outcome of the N2OFF merger in September 2025?

In September 2025, N2OFF shareholders approved the merger with SciSparc’s majority-owned subsidiary MitoCareX, a drug discovery company targeting resistant cancers including pancreatic and non-small cell lung cancer.

What strategic initiative did SciSparc resolve to launch in September 2025?

In September 2025, SciSparc resolved to launch an innovative quantum computing-enabled 3D protein modeling initiative aimed at revolutionizing AI drug discovery.

What was the status of SciSparc's collaboration with Clearmind Medicine in September 2024?

In September 2024, the collaboration between SciSparc and Clearmind Medicine led to the publication of an international patent application for an innovative MDMA-based combination treatment.

What regulatory milestone did SciSparc achieve in September 2024 for its Tourette syndrome treatment?

In September 2024, SciSparc secured FDA green light for the US launch of its pivotal Phase IIb clinical trial for a breakthrough Tourette syndrome treatment.